$TCRT

ZIOPHARM ONCOLOGY INC

CIK:0001107421|SEC Filings

CONDENSED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
CONDENSED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Revenue	$ 0	$ 0	$ 0	$ 2
Operating expenses:
Research and development	388	185	814	531
General and administrative	564	854	1,150	1,603
Total operating expenses	952	1,039	1,964	2,134
Loss from operations	(952)	(1,039)	(1,964)	(2,132)
Other income (expense):
Change in fair value of warrant liability	0	(31)	0	(31)
Other income (expense), net	0	19	6	39
Other income (expense), net	0	(12)	6	8
Net loss	$ (952)	$ (1,051)	$ (1,958)	$ (2,124)
Earnings per share, Basic	$ (0.41)	$ (0.63)	$ (0.85)	$ (1.3)
Earnings per share, Diluted	$ (0.41)	$ (0.63)	$ (0.85)	$ (1.3)
Weighted average common shares outstanding, basic	2,431,695	1,676,345	2,397,404	1,639,123
Weighted average common shares outstanding, diluted	2,431,695	1,676,345	2,397,404	1,639,123

CONDENSED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities:
Net loss	$ (1,958)	$ (2,124)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	17	0
Change in fair value of warrant liability	0	31
Common stock issued for consulting services rendered, including board fees and salary	275	0
Stock-based compensation	113	252
Changes in operating assets and liabilities:
Receivables	3	3
Prepaid expenses and other current assets	169	(18)
Accounts payable	118	293
Accrued expenses	(68)	90
Net cash flows from operating activities	(1,331)	(1,473)
Cash flows from financing activities:
Proceeds from the issuance of common stock and pre funded warrants, net of offering costs	0	1,911
Proceeds from sale of Series A-1 preferred stock	0	500
Proceeds from sale of Series A-2 preferred stock	0	850
Proceeds from equity line of credit, net of cost	70	0
Net cash flows from financing activities	70	3,261
Net increase (decrease) in cash, cash equivalents	(1,261)	1,788
Cash and cash equivalents, beginning of period	1,385	1,091
Cash and cash equivalents, end of period	$ 124	$ 2,879

CONDENSED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 124	$ 1,385
Receivables	0	3
Prepaid expenses and other current assets, current	542	600
Total current assets	666	1,988
Property and equipment, net	74	91
Prepaid expenses and other assets, non current	776	887
Total assets	1,516	2,966
Current liabilities:
Accounts payable	732	613
Accrued expenses	132	200
Total current liabilities	864	813
Total liabilities	864	813
Commitments and contingencies (Note 4)
Stockholders' equity
Common stock $0.001 par value; 50,000,000 shares authorized, 2,486,140 and 2,349,480 shares issued and outstanding at June 30, 2026 and at December 31, 2025, respectively	2	2
Additional paid-in capital	927,230	926,773
Accumulated deficit	(926,580)	(924,622)
Total stockholders' equity	652	2,153
Total liabilities and stockholders' equity	1,516	2,966
Series A-1 Preferred Stock
Stockholders' equity
Preferred stock value	0	0
Series A-2 Preferred Stock
Stockholders' equity
Preferred stock value	$ 0	$ 0